Franck Morin
Intergroupe Francophone de Cancérologie Thoracique · 348 works · 7,954 citations · h-index 38
Top works
- Lung cancer in never smokers – A review
- Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
- Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
- Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network
- Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial
- COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study
- Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002
- Femtosecond fiber chirped- and divided-pulse amplification system
- Biomarkers (BM) France: Results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts).
- Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study
- Microjoule femtosecond fiber laser at 16 μm for corneal surgery applications
- Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial
- A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial
- 1389P IFCT-1602 CHIVA2 phase II trial: Nivolumab in previously treated HIV-patients with advanced non-small cell lung cancer (NSCLC)
- IFCT-0401 Trial: A Phase II Study of Gefitinib Administered as First-Line Treatment in Advanced Adenocarcinoma with Bronchioloalveolar Carcinoma Subtype
- 1326P Osimertinib in patients with EGFR-mutated NSCLC and leptomeningeal or brain metastases: Results of the IFCT-1804 ORBITAL trial
- Energy scaling of a nonlinear compression setup using passive coherent combining
- BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers
- Passive coherent combination of two ultrafast rod type fiber chirped pulse amplifiers
- Customized Adjuvant Phase II Trial in Patients With Non–Small-Cell Lung Cancer: IFCT-0801 TASTE